Suppr超能文献

肾癌小鼠模型中的异常上皮形态和持续的表皮生长因子受体信号传导。

Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma.

作者信息

Morris Zachary S, McClatchey Andrea I

机构信息

Massachusetts General Hospital Center for Cancer Research and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.

出版信息

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9767-72. doi: 10.1073/pnas.0902031106. Epub 2009 Jun 1.

Abstract

The epidermal growth factor receptor (EGFR) has frequently been implicated in hyperproliferative diseases of renal tubule epithelia. We have shown that the NF2 tumor suppressor Merlin inhibits EGFR internalization and signaling in a cell contact-dependent manner. Interestingly, despite the paucity of recurring mutations in human renal cell carcinoma (RCC), homozygous mutation of the NF2 gene is found in approximately 2% of RCC patient samples in the Sanger COSMIC database. To examine the roles of Merlin and EGFR in kidney tumorigenesis, we generated mice with a targeted deletion of Nf2 in the proximal convoluted epithelium using a Villin-Cre transgene. All of these mice developed intratubular neoplasia by 3 months, which progressed to invasive carcinoma by 6-10 months. Kidneys from these mice demonstrated marked hyperproliferation and a concomitant increase in label-retaining putative progenitor cells. Early lumen-filling lesions in this model exhibited hyperactivation of EGFR signaling, altered solubility of adherens junctions components, and loss of epithelial polarity. Renal cortical epithelial cells derived from either early or late lesions were dependent on EGF for in vitro proliferation and were arrested by pharmacologic inhibition of EGFR or re-expression of Nf2. These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vitro passage. Treatment of Vil-Cre;Nf2(lox/lox) mice with the EGFR inhibitor erlotinib halted the proliferation of tumor cells. These studies give added credence to the role of EGFR signaling and perhaps Nf2 deficiency in RCC and describe a rare and valuable mouse model for exploring the molecular basis of this disease.

摘要

表皮生长因子受体(EGFR)常与肾小管上皮的过度增殖性疾病有关。我们已经表明,NF2肿瘤抑制因子Merlin以细胞接触依赖的方式抑制EGFR的内化和信号传导。有趣的是,尽管人类肾细胞癌(RCC)中反复出现的突变很少,但在Sanger COSMIC数据库中约2%的RCC患者样本中发现了NF2基因的纯合突变。为了研究Merlin和EGFR在肾肿瘤发生中的作用,我们使用Villin-Cre转基因在近端曲管上皮中靶向缺失Nf2基因,生成了小鼠。所有这些小鼠在3个月时都发生了肾小管内瘤变,并在6至10个月时发展为浸润性癌。这些小鼠的肾脏表现出明显的过度增殖,同时标记保留的假定祖细胞数量增加。该模型中早期的管腔填充性病变表现出EGFR信号的过度激活、黏附连接成分溶解度的改变以及上皮极性的丧失。来自早期或晚期病变的肾皮质上皮细胞在体外增殖依赖于表皮生长因子(EGF),并通过EGFR的药物抑制或Nf2的重新表达而停滞。这些细胞在体外传代前皮下注射到免疫缺陷小鼠体内后形成恶性肿瘤。用EGFR抑制剂厄洛替尼治疗Vil-Cre;Nf2(lox/lox)小鼠可使肿瘤细胞的增殖停止。这些研究进一步证实了EGFR信号传导以及可能的Nf2缺陷在RCC中的作用,并描述了一种罕见且有价值的小鼠模型,用于探索这种疾病的分子基础。

相似文献

引用本文的文献

3
Renal Cell Carcinoma of Variant Histology: Biology and Therapies.肾细胞癌的变异组织学:生物学和治疗。
Hematol Oncol Clin North Am. 2023 Oct;37(5):977-992. doi: 10.1016/j.hoc.2023.04.019. Epub 2023 May 25.
7
Analysis of the role of the Hippo pathway in cancer.分析 Hippo 通路在癌症中的作用。
J Transl Med. 2019 Apr 8;17(1):116. doi: 10.1186/s12967-019-1869-4.

本文引用的文献

1
Origin of renal cell carcinomas.肾细胞癌的起源
Clin Transl Oncol. 2008 Nov;10(11):697-712. doi: 10.1007/s12094-008-0276-8.
5
Epithelial junctions and polarity: complexes and kinases.上皮连接与极性:复合物和激酶
Curr Opin Nephrol Hypertens. 2008 Sep;17(5):506-12. doi: 10.1097/MNH.0b013e32830baaae.
9
The Catalogue of Somatic Mutations in Cancer (COSMIC).癌症体细胞突变目录(COSMIC)。
Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11. doi: 10.1002/0471142905.hg1011s57.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验